Scarica l'app Stockscreener
10.27
1.78%
0.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.09
Aprire:
$10.01
Volume 24 ore:
1.43M
Relative Volume:
1.05
Capitalizzazione di mercato:
$1.23B
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-16.56
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
+7.54%
1M Prestazione:
+3.11%
6M Prestazione:
-21.42%
1 anno Prestazione:
-25.85%
Intervallo 1D:
$9.8686
$10.29
Intervallo di 1 settimana:
$9.305
$10.44
Portata 52W:
$8.05
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Confronta NEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.27 | 1.23B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Bank of Montreal Can - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting - Business Wire
Learn to Evaluate (NEO) using the Charts - news.stocktradersdaily.com
Deep Dive Into NeoGenomics Stock: Analyst Perspectives (5 Ratings) - Benzinga
BofA Securities Adjusts Price Target on NeoGenomics to $12 From $16, Maintains Neutral Rating - marketscreener.com
Former AstraZeneca exec takes over as CEO of $660M Fort Myers lab firm - Business Observer
Form DEF 14A NEOGENOMICS INC For: Dec 31 - StreetInsider
SEC Form DEF 14A filed by NeoGenomics Inc. - Quantisnow
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 68% as the stock sheds US$85m this past week - simplywall.st
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 - BioSpace
NeoGenomics acquires Pathline - Medical Buyer
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
NeoGenomics expands with Pathline acquisition in Northeast US - Investing.com Australia
NeoGenomics expands with Pathline acquisition in Northeast US By Investing.com - Investing.com South Africa
NeoGenomics completes acquisition of Pathline - Gulfshore Business
NeoGenomics Completes Acquisition of Pathline - BioSpace
NeoGenomics Closes Pathline Acquisition - MarketScreener
NeoGenomics (NEO) Completes Acquisition of Pathline - StreetInsider
NeoGenomics Schedules its Second Quarter Earnings Release for July 30, 2019 - ACCESS Newswire
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore - ACCESS Newswire
NeoGenomics stock hits 52-week low at $8.9 amid challenges By Investing.com - Investing.com South Africa
NeoGenomics stock hits 52-week low at $8.9 amid challenges - Investing.com
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) - Yahoo Finance
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire
NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019 - ACCESS Newswire
NeoGenomics announces CEO transition - MSN
New CEO assumes role at NeoGenomics - Gulfshore Business
(NEO) Trading Report - news.stocktradersdaily.com
NeoGenomics appoints Tony Zook as CEO - Investing.com
NeoGenomics, Inc. Announces CEO Changes - MarketScreener
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - BioSpace
NeoGenomics appoints Tony Zook as CEO By Investing.com - Investing.com Australia
NeoGenomics Appoints Tony Zook Chief Executive - MarketScreener
NeoGenomics' New CEO Zook Takes Over as Smith Retires - MarketWatch
Tony Zook Assumes Role As Chief Executive Officer Of Neogenomics - MarketScreener
Benchmark maintains Hold on Neogenomics stock, reiterates price target By Investing.com - Investing.com Canada
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance
Piper Sandler maintains Neogenomics stock with $18 target - Investing.com
Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK
NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia
NeoGenomics Promotes Warren Stone to President & COO - TipRanks
Fort Myers-based NeoGenomics names new COO - Gulfshore Business
Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com
NeoGenomics elevates Warren Stone to President and COO - Investing.com
NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):